» Articles » PMID: 24570176

Mosaic RNA Phage VLPs Carrying Domain III of the West Nile Virus E Protein

Overview
Journal Mol Biotechnol
Publisher Springer
Date 2014 Feb 27
PMID 24570176
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The virus-neutralising domain III (DIII) of the West Nile virus glycoprotein E was exposed on the surface of RNA phage AP205 virus-like particles (VLPs) in mosaic form. For this purpose, a 111 amino acid sequence of DIII was added via amber or opal termination codons to the C-terminus of the AP205 coat protein, and mosaic AP205-DIII VLPs were generated by cultivation in amber- or opal-suppressing Escherichia coli strains. After extensive purification to 95 % homogeneity, mosaic AP205-DIII VLPs retained up to 11-16 % monomers carrying DIII domains. The DIII domains appeared on the VLP surface because they were fully accessible to anti-DIII antibodies. Immunisation of BALB/c mice with AP205-DIII VLPs resulted in the induction of specific anti-DIII antibodies, of which the level was comparable to that of the anti-AP205 antibodies generated against the VLP carrier. The AP205-DIII-induced anti-DIII response was represented by a significant fraction of IgG2 isotype antibodies, in contrast to parallel immunisation with the DIII oligopeptide, which failed to induce IgG2 isotype antibodies. Formulation of AP-205-DIII VLPs in alum adjuvant stimulated the level of the anti-DIII response, but did not alter the fraction of IgG2 isotype antibodies. Mosaic AP205-DIII VLPs could be regarded as a promising prototype of a putative West Nile vaccine.

Citing Articles

Antigen self-anchoring onto bacteriophage T5 capsid-like particles for vaccine design.

Vernhes E, Cherif L, Ducrot N, Vanbergue C, Ouldali M, Zig L NPJ Vaccines. 2024; 9(1):6.

PMID: 38177231 PMC: 10766600. DOI: 10.1038/s41541-023-00798-5.


Bacteriophage Virus-Like Particles: Platforms for Vaccine Design.

Tumban E Methods Mol Biol. 2023; 2738:411-423.

PMID: 37966612 DOI: 10.1007/978-1-0716-3549-0_24.


A Plant-Produced Virus-Like Particle Displaying Envelope Protein Domain III Elicits an Immune Response Against West Nile Virus in Mice.

Stander J, Chabeda A, Rybicki E, Meyers A Front Plant Sci. 2021; 12:738619.

PMID: 34589108 PMC: 8475786. DOI: 10.3389/fpls.2021.738619.


RNA Phage VLP-Based Vaccine Platforms.

Peabody D, Peabody J, Bradfute S, Chackerian B Pharmaceuticals (Basel). 2021; 14(8).

PMID: 34451861 PMC: 8401894. DOI: 10.3390/ph14080764.


Recent Advances in the Development of Virus-Like Particle-Based Flavivirus Vaccines.

Zhang N, Li C, Jiang S, Du L Vaccines (Basel). 2020; 8(3).

PMID: 32867194 PMC: 7565697. DOI: 10.3390/vaccines8030481.


References
1.
Kozlovska T, Cielens I, Vasiljeva I, Strelnikova A, Kazaks A, Dislers A . RNA phage Q beta coat protein as a carrier for foreign epitopes. Intervirology. 1996; 39(1-2):9-15. DOI: 10.1159/000150469. View

2.
Kazaks A, Dishlers A, Pumpens P, Ulrich R, Kruger D, Meisel H . Mosaic particles formed by wild-type hepatitis B virus core protein and its deletion variants consist of both homo- and heterodimers. FEBS Lett. 2003; 549(1-3):157-62. DOI: 10.1016/s0014-5793(03)00805-6. View

3.
Siirin M, Travassos da Rosa A, Newman P, Weeks-Levy C, Coller B, Xiao S . Evaluation of the efficacy of a recombinant subunit West Nile vaccine in Syrian golden hamsters. Am J Trop Med Hyg. 2008; 79(6):955-62. PMC: 2765405. View

4.
Lee J, Chu J, Ng M . Quantifying the specific binding between West Nile virus envelope domain III protein and the cellular receptor alphaVbeta3 integrin. J Biol Chem. 2005; 281(3):1352-60. DOI: 10.1074/jbc.M506614200. View

5.
Volk D, Beasley D, Kallick D, Holbrook M, Barrett A, Gorenstein D . Solution structure and antibody binding studies of the envelope protein domain III from the New York strain of West Nile virus. J Biol Chem. 2004; 279(37):38755-61. DOI: 10.1074/jbc.M402385200. View